Comforting,Supportive and Illuminating viewpoints with specifics: ALL IN ONE POST! versus what's been witnessed here (posts are invariably devoid of additional content, let alone contribution, non constructive:being critical of mgt and only exemplary in the pissing and moaning of "Monday evening quarterbacking").
Welcome Notbrad and thanks for sharing! a breath of fresh air along with Mewards posts
Candidly, even those who shared their past ownership with DNDN as well as also own NWBO have IMHO failed to post the following STRATEGIC ISSUES until the past 6 mos!!: 1)the differences of NWBO vs DNDN 2)why no one else responded to BasinStBlues: "Why No Institutional Interest in NWBO" 3)Why did everyone here missed markets infatuation with CART CI co's 4)Even more recently, no one labelled NWBO as either the DARK HORSE and more importantly dealing with DARWINIAN SURVIVAL.
Reinforces strongly my entrenched views of posters inability to vitally integrate the above KEY Issues vs their myopic scientific orientation without the all important business dynamics at play, let alone some of the competitive developments.
As I've stated: Different Strokes for Different Folks and mostly with varying mindsets of the retail mindset largely IMHO that has begun the mental migration of the big picture.
With few exceptions, this from Notbrad being one of those, posts are invariably devoid of content, let alone contribution; forget about impact, with most solely on the critique level mindfully strategic negligent of the extreme valuation divide between CI's and this still DARK HORSE!
To say the least this is a CANDID REALISTIC ASSESSMENT:(should one ply thru the voluminous posts for quite a while: even pre 2014!).
To each his own!
Rhetorically speaking: The above is a realistic assessment for the need of adding to one's skillsets to be a better biotech investor requires a LOT: Will you REINVENT YOURSELF!or will you be stuck in your narrow perspective!
Thanks a lot, Notbrad. You truthfully revealed the old days of DNDN. If DNDN obtained the approval from FDA at that time, DNDN would be 5 years ahead of JNJ and should be the leader of dendritic field now. The downfall of DNDN has more reasons attributed to the masterminds behind the scene. FDA is more about interests and politics than human life.